Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp123 | Endocrine Tumours | ECE2017

Outcome of patients with adrenocortical cancer after discontinuation of adjuvant mitotane therapy

Terzolo Massimo , Basile Vittoria , Megerle Felix , Hermann Wiebke , Cicciarella Federica , Libe Rossella , Baudin Eric , Haak Harm , Mannelli Massimo , Boscaro Marco , Quinkler Marcus , Bourdeau Isabelle , Perotti Paola , Hahner Stefanie , Beuschlein Felix , Fassnacht Martin

Background: Adjuvant mitotane therapy is frequently used in Europe following surgery for adrenocortical carcinoma (ACC). Management of adjuvant mitotane is mainly empirical and a major open question is the optimal duration of therapy, because no study has ever addressed this issue.Objective: We aimed to assess the outcome of ACC patients who were treated with adjuvant mitotane for at least one year following surgery and then discontinued therapy for othe...

ea0073oc11.5 | Oral Communications 11: Adrenal and Cardiovascular Endocrinoloyg | ECE2021

Results of the ADIUVO trial, the first randomized study on post-operative adjuvant mitotane in patients with adrenocortical carcinoma

Terzolo Massimo , Fassnacht Martin , Perotti Paola , Libè Rossella , Lacroix Andre , Kastelan Darko , R. Haak Harm , Arlt Wiebke , Loli Paola , Decoudier Benedicte , Lasolle Hélène , Bancos Irina , Quinkler Marcus , Barisson Villares Fragoso Maria Candida , Canu Letizia , Puglisi Soraya , Calabrese Anna , Kroiss Matthias , Dusek Tina , Bourdeau Isabelle , Baudin Eric , Berchialla Paola , Beuschlein Felix , Bertherat Jerome , Berruti Alfredo

BackgroundThe ESE-ENSAT guidelines suggest adjuvant mitotane for patients with adrenocortical carcinoma (ACC) at high risk of recurrence following radical surgery. This indication has a limited evidence base, lacking results from randomized controlled trials. No suggestion is available in low-risk patients, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane (MIT) treatm...

ea0081oc2.3 | Oral Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Loss of lysine demethylase KDM1A in GIP-dependent bilateral macronodular adrenal hyperplasia with Cushing’s syndrome

Chasseloup Fanny , Bourdeau Isabelle , Tabarin Antoine , Regazzo Daniela , Dumontet Charles , Ladurelle Nataly , Tosca Lucie , Amazit Larbi , Proust Alexis , Scharfmann Raphael , Fiore Frederic , Tsagarakis Stylianos , Vassiliadi Dimitra , Maiter Dominique , Young Jacques , Lecoq Anne-Lise , Demeocq Vianney , Salenave Sylvie , Lefebvre Herve , Cloix Lucie , Emy Philippe , Desailloud Rachel , Vezzosi Delphine , Scaroni Carla , Barbot Mattia , de Herder Wouter , Pattou Francois , Tetreault Martine , Corbeil Gilles , Dupeux Margot , Lambert Benoit , Tachdjian Gerard , Guiochon-Mantel Anne , Beau Isabelle , Chanson Philippe , Viengchareun Say , Lacroix Andre , Bouligand Jerome , Kamenicky Peter

Context: Primary bilateral macronodular adrenal hyperplasia (PBMAH) with glucose-dependent insulinotropic polypeptide (GIP)-dependent CushingÂ’s syndrome is caused by ectopic expression of GIP receptor in the adrenal tissue. The bilateral nature of this adrenal disease suggests germline genetic predisposition. We aimed to identify the molecular driver event responsible for ectopic GIP receptor expression in PBMAH.Methods: We conducted an internationa...